Real-world study confirms efficacy of anlotinib in soft tissue sarcoma
After the ALTER0203 clinical trial demonstrated the antitumor effects of anlotinib on advanced soft tissue sarcoma (STS) after the failure of standard chemotherapy, researchers sought to confirm the efficacy in a real-world setting.
Data from 209 patients with unresectable locally advanced or metastatic STS who received ≥1 dose of anlotinib were retrospectively analyzed. The median age was 48 (range 11-85) years. Patients were followed for a median of 18.7 months. The median progression-free survival and overall survival were 6.1 months [95% confidence interval (CI): 4.9-7.2], and 16.4 months (95% CI: 13.6-19.1), respectively. The objective response rate was 13.4%.
The following were significantly associated with progression-free survival:
-Nutritional status
-Eastern Cooperative Oncology Group (ECOG) performance status
-Anlotinib treatment patterns (combination therapy or switch maintenance therapy vs. monotherapy)
The following were predictive of overall survival:
-Pathological grade
-Nutritional status
-ECOG performance status
-anlotinib treatment patterns
A dose reduction was needed in 14.8% of patients and treatment discontinuation in 12% of patients due to anlotinib-related toxicity.
Referene
Zhang RS, Liu J, Deng YT, et al. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era. Cancer Med. 2022;doi: 10.1002/cam4.4613. Epub ahead of print. PMID: 35191609.
